<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04889989</url>
  </required_header>
  <id_info>
    <org_study_id>NEU_2020_02</org_study_id>
    <nct_id>NCT04889989</nct_id>
  </id_info>
  <brief_title>Microwave Ablation in Chinese Patients With Lung Tumors</brief_title>
  <official_title>A Single-Arm, Prospective, Multicenter Study to Evaluate the Effectiveness and Safety of the NeuWave Certus Microwave Ablation System in Chinese Patients With Primary or Secondary Tumors in the Lung</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ethicon, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ethicon, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Adult patients with non-small cell lung cancer (NSCLC) or oligometastatic lung tumors will&#xD;
      all receive microwave ablation (MWA) performed percutaneously by doctors who are experienced&#xD;
      in lung tumor ablation. 120 patients will participate across 8 clinical study sites all in&#xD;
      China.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single-arm, prospective, multicenter clinical trial with a performance goal</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Technical Efficacy Rate</measure>
    <time_frame>30 days (+/- 7) post-ablation</time_frame>
    <description>Percentage of tumors that are completely covered by the ablation zone with no sign of pathological enhancement according to the lung contrast-enhanced CT assessment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Technical Success Rate</measure>
    <time_frame>Ablation Day (day 0)</time_frame>
    <description>Percentage of tumors that achieve A0 or A1 ablation classification determinations (i.e., complete tumor ablation with a surrounding margin) in the lung CT immediately following the initial ablation procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local Tumor Progression</measure>
    <time_frame>1 year post-ablation</time_frame>
    <description>Local tumor progression and time to local tumor progression of any original-ablated tumor(s)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival</measure>
    <time_frame>1 year post-ablation</time_frame>
    <description>Length of time the patient is still alive after the original ablation procedure and with no evidence of any tumor progression (local, regional, or distant)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>1 year post-ablation</time_frame>
    <description>Length of time the patient is still alive after the original ablation procedure within the study duration</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Cancer of the Lung</condition>
  <arm_group>
    <arm_group_label>Microwave Ablation of Lung Tumor</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Adult patients with non-small cell lung cancer (NSCLC) or oligometastatic lung tumors who plan to receive percutaneous microwave ablation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Microwave Ablation</intervention_name>
    <description>Percutaneous microwave ablation using the NeuWave Microwave Ablation System for non-small cell lung cancer or oligometastatic lung tumors</description>
    <arm_group_label>Microwave Ablation of Lung Tumor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed the informed consent form and willing to fulfill the study-related assessments&#xD;
             and procedure schedule.&#xD;
&#xD;
          2. Lung tumor patients ≥ 18 years of age who are ineligible for/decline surgery and who&#xD;
             plan to receive microwave ablation therapy.&#xD;
&#xD;
          3. ECOG performance status score of 0-2.&#xD;
&#xD;
          4. Patients with stages IA1-IA2 NSCLC with documented results from a biopsy or patients&#xD;
             with clinically diagnosed oligometastatic lung tumor.&#xD;
&#xD;
          5. Tumor(s) to be ablated in a single surgery should be a maximum of one NSCLC tumor or a&#xD;
             maximum of three ipsilateral oligometastatic lung tumors.&#xD;
&#xD;
          6. Tumor(s) to be ablated in a single surgery should be ≤ 2cm, locate in the outer&#xD;
             two-thirds of a lung, not closer than 1 cm from the hilum of lung, great vessels,&#xD;
             principal bronchus, trachea or esophagus, and not contiguous with the pleura.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or breast-feeding.&#xD;
&#xD;
          2. Patients with implantable pacemakers or other electronic implants.&#xD;
&#xD;
          3. Oligometastatic tumors patients whose primary lesion cannot be controlled or have&#xD;
             widely metastases, in the opinion of the investigator and/or treating oncologist.&#xD;
&#xD;
          4. Any planned concurrent procedure at the time of ablation.&#xD;
&#xD;
          5. Planned treatment for other tumors in the same side lung during the study period.&#xD;
&#xD;
          6. With a skin infection or ulceration at the site to be punctured by probe(s).&#xD;
&#xD;
          7. Clinical or imaging findings consistent with an active pulmonary infection.&#xD;
&#xD;
          8. Patients with severe pulmonary fibrosis in the area intended to ablate, especially&#xD;
             drug-induced pulmonary fibrosis.&#xD;
&#xD;
          9. Patients with prior radiotherapy in the area intended to ablate.&#xD;
&#xD;
         10. Patients with uncontrolled malignant pleural effusion at the lung side with tumor to&#xD;
             ablate.&#xD;
&#xD;
         11. Tumors where the anticipated zone of ablation would encompass significant (in the&#xD;
             opinion of the treating physician) emphysematous or bullous disease.&#xD;
&#xD;
         12. The investigator anticipates that the ablation zone of the multiple tumor(s) to be&#xD;
             ablated may have overlapping ablation zones.&#xD;
&#xD;
         13. Patients who have received lung ablation or surgical resection therapy within 30 days&#xD;
             prior to the ablation procedure under study and those who plan to receive lung tumor&#xD;
             ablation or surgical resection therapy or radiation therapy on the ablated lung side&#xD;
             before completing the primary efficacy endpoint assessment approximately 30 days after&#xD;
             the ablation procedure.&#xD;
&#xD;
         14. Patients who received systemic therapy such as chemotherapy, targeted drug therapy, or&#xD;
             immunotherapy within 7 days prior to the ablation procedure under study, and patients&#xD;
             who had a systemic treatment plan such as chemotherapy, targeted drug therapy,&#xD;
             immunotherapy, etc. before completing the primary efficacy endpoint assessment&#xD;
             approximately 30 days after the ablation procedure.&#xD;
&#xD;
         15. Patients with uncorrectable coagulopathy based on investigator judgment.&#xD;
&#xD;
         16. Patients with a platelet count ≤ 50 × 109/L.&#xD;
&#xD;
         17. Patients who cannot discontinue antiplatelet medication (e.g., aspirin, clopidogrel,&#xD;
             prasugrel, ticagrelor) at least 5 days before the ablation procedure through 24 hours&#xD;
             post-procedure.&#xD;
&#xD;
         18. Patients who cannot discontinue anticoagulant medication (e.g., rivaroxaban, apixaban,&#xD;
             dabigatran, edoxaban) at least 3 days before the ablation procedure through 24 hours&#xD;
             post-procedure.&#xD;
&#xD;
         19. Patients who cannot discontinue warfarin before at least 5 days before the ablation&#xD;
             procedure of the study or have an INR &gt; 1.5.&#xD;
&#xD;
         20. As judged by the investigator, the patient has hypertension that cannot be effectively&#xD;
             controlled by pharmacological treatments.&#xD;
&#xD;
         21. Severe hepatic, renal, cardiac, pulmonary or cerebral insufficiency, severe anemia,&#xD;
             dehydration, and severe nutrition and metabolism disorders, which cannot be corrected&#xD;
             or improved within a short term; or serious systemic infection; or severe&#xD;
             neuromuscular diseases.&#xD;
&#xD;
         22. Expected survival less than 6 months.&#xD;
&#xD;
         23. Participation in any other interventional clinical study within 30 days before&#xD;
             screening.&#xD;
&#xD;
         24. Physical or psychological condition which would impair study participation.&#xD;
&#xD;
         25. Patient is judged unsuitable for study participation by the investigator for any other&#xD;
             reason.&#xD;
&#xD;
             Intra-Ablation Exclusion Criteria:&#xD;
&#xD;
         26. Before ablation probe puncture on the skin, patient is judged unsuitable for study&#xD;
             participation due to intolerance to anesthesia.&#xD;
&#xD;
         27. Before ablation probe puncture on the skin, patient is judged unsuitable for study&#xD;
             participation due to presenting any other condition.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Erin Meyers, MBA</last_name>
    <phone>(908) 808-6302</phone>
    <email>eprifog1@its.jnj.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pecking University Shenzhen Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Fujian Medical University</name>
      <address>
        <city>Fujian</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Fourth Affiliated Hospital of Harbin Medical University</name>
      <address>
        <city>Harbin</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Henan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hunan Cancer Hospital</name>
      <address>
        <city>Hunan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Suzhou Medical University</name>
      <address>
        <city>Suzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 12, 2021</study_first_submitted>
  <study_first_submitted_qc>May 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2021</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Johnson &amp; Johnson Medical Device Companies have an agreement with the Yale Open Data Access (YODA) Project to serve as the independent review panel for evaluation of requests for clinical study reports and participant level data from investigators and physicians for scientific research that will advance medical knowledge and public health. Requests for access to the study data can be submitted through the YODA Project site at http://yoda.yale.edu.</ipd_description>
    <ipd_url>http://yoda.yale.edu</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

